用单克隆抗体检测黄热病疫苗病毒的包膜糖蛋白。

Examination of the envelope glycoprotein of yellow fever vaccine viruses with monoclonal antibodies.

作者信息

Barrett A D, Pryde A, Medlen A R, Ledger T N, Whitby J E, Gibson C A, DeSilva M, Groves D J, Langley D J, Minor P D

机构信息

Department of Microbiology, University of Surrey, Guildford, UK.

出版信息

Vaccine. 1989 Aug;7(4):333-6. doi: 10.1016/0264-410x(89)90196-5.

DOI:10.1016/0264-410x(89)90196-5

PMID:2479185

Abstract

Two panels of envelope glycoprotein reactive monoclonal antibodies (mAbs) were prepared against yellow fever (YF) 17D vaccine viruses. Five mAbs were prepared against the World Health Organization 17D-204 avian leukosis virus-free secondary seed virus and eight mAbs against 17DD vaccine manufactured in Brazil. The majority of these mAbs were type-specific and displayed differing reactions in neutralization tests. One, B14, would only neutralize YF vaccine virus grown in invertebrate cells. Others would differentiate 17D-204 and 17DD vaccines, from different manufacturers, in neutralization tests when the viruses were grown in vertebrate cells. The data indicate that heterogeneity exists between the epitopes that elicit neutralizing antibody on YF vaccine from different manufacturers.

摘要

制备了两组针对黄热病（YF）17D疫苗病毒的包膜糖蛋白反应性单克隆抗体（mAb）。一组是针对世界卫生组织17D - 204无禽白血病病毒二级种子病毒制备的5种单克隆抗体，另一组是针对巴西生产的17DD疫苗制备的8种单克隆抗体。这些单克隆抗体大多具有型特异性，在中和试验中表现出不同的反应。其中一种，即B14，仅能中和在无脊椎动物细胞中生长的YF疫苗病毒。当病毒在脊椎动物细胞中生长时，其他单克隆抗体在中和试验中能够区分来自不同制造商的17D - 204和17DD疫苗。数据表明，不同制造商的YF疫苗上引发中和抗体的表位之间存在异质性。